Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.

Tapinarof proven safe, effective for psoriasis in phase II trial

11 Mar 2019
From the survey conducted, it is found that more than 80% of patients with psoriasis have experienced discrimination or humiliation across the world.

A phase II study has shown the efficacy and safety of tapinarof cream in adult patients with psoriasis.

The investigators assessed the safety and efficacy of tapinarof in a new cream formulation at two concentrations and with two application frequencies in this double-blind, vehicle-controlled, randomized, six-arm trial. Participants included adults with psoriasis with body surface involvement ≥1 percent and ≤15 percent and Physician Global Assessment (PGA) score ≥2 at baseline.

PGA of 0 or 1 at week 12 and a 2-grade improvement from baseline were the primary endpoints. Further analyses included assessment of ≥75-percent improvement of Psoriasis Area and Severity Index (PASI) and mean percent change in PASI and body surface area involvement.

Patients in the tapinarof groups had statistically significantly higher (at a 0.05 significance level) treatment success, defined by PGA 0 or 1 and a 2-grade improvement at week 12 (65 percent [1% twice daily], 56 percent [1% once daily], 46 percent [0.5% twice daily] and 36 percent [0.5% once daily]) than those in the vehicle groups (11 percent [twice daily] and 5 percent [once daily]).

Treatment success was maintained for 4 weeks post-treatment.

However, patients treated with tapinarof (85/152; 56 percent) were more likely to experience treatment-emergent adverse events (TEAEs) than those in the vehicle group (19/75; 25 percent). TEAEs were mild-to-moderate in intensity. Moreover, severe TEAEs were reported in all tapinarof groups except the 0.5% once-daily group.

Large confirmation trials are warranted, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.